Evidence Hub

Cefmetazole-Induced Vitamin K-Dependent Coagulopathy Associated with Life-Threatening Gastrointestinal Bleeding in a Critically Ill Older Patient: A Case Report

Nishida T, Muroya D, Shimokobe H, Taniwaki S

Surgical case reports, 2026

Abstract

Introduction: Cefmetazole (CMZ) is frequently used in abdominal surgery and critical care settings. Although cephalosporins containing an N-methyl-tetrazole-thiol (NMTT) side chain interfere with vitamin K metabolism, life-threatening clinically significant bleeding associated with CMZ-induced coagulopathy has rarely been reported.

Case presentation: A 78-year-old woman with severe infections developed severe vitamin K-dependent coagulopathy during CMZ therapy. She subsequently experienced worsening upper gastrointestinal bleeding complicated by hemorrhagic shock in the setting of severe vitamin K-dependent coagulopathy despite preserved platelet counts and fibrinogen levels. Coagulation abnormalities rapidly improved following vitamin K administration, and no recurrence was observed after CMZ discontinuation.

Conclusions: This case report highlights CMZ-induced vitamin K-dependent coagulopathy as a rare but life-threatening adverse event in critically ill older patients. Coagulation parameters should be carefully monitored during CMZ therapy, particularly in high-risk patients.

How strong is the evidence?

Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free